ArticleAmerican journal of translational research2025
Screening of RNA methyltransferase NSP16 inhibitors against SARS-CoV-2 coronavirus and study of related mechanisms.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to determine the abilities of several drugs to block the second methylation process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA with non-structural protein 16 (NSP16) and expose the virus to the innate immune mechanism of the host for the purpose of improving infection control and drug development for COVID-19.
methodsRecombinant prokaryotic expression plasmids PET30a-NSP16 and PET15b-NSP10 and a plasmid for preserving the untranslated region (UTR) sequences, pUC57-UTR, were constructed. The obtained UTR template was transcribed in vitro to obtain RNAs. Then, bioluminescence was used to determine the K
resultsThe catalytic subunit NSP16 and stimulatory subunit NSP10 of SARS-COV-2 2'-O-MTase were successfully expressed. The K
conclusionFour drugs with potential inhibitory activity were examined. Among them, cladribine and didanosine have weak inhibitory effects on SARS-CoV-2 NSP16 and, therefore, are not suitable for clinical application. Sinefungin has the strongest inhibitory effect, and ebselen ranks second. Therefore, they can be regarded as qualified clinical candidates for SARS-CoV-2 treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.